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Background
The clinical presentation and course of Langerhans cell histiocytosis (LCH) are variable, 
ranging from an isolated, spontaneously remitting bone lesion to multisystem disease 
with risk organ involvement. Treatment of LCH ranges from a wait-and-see attitude to 
intensive multidrug therapy and, in some cases, bone marrow transplantation. It is 
necessary to develop an objective score for assessing disease activity in patients with LCH. 
We propose a new clinical scoring system to evaluate disease activity at diagnosis that 
can predict the clinical outcomes of LCH and correlate it with clinical courses.
Methods
Clinical data, obtained from children diagnosed with LCH at Asan Medical Center and 
Hanyang University Hospital between March 1998 and February 2009, were studied 
retrospectively. The scoring system was developed according to the basic biological data, 
radiological findings, and physical findings and applied to a database containing 
information on 133 patients.
Results
The median age of the 133 patients (74 male, 59 female) was 52 months (range, 0.6-178 
months), and LCH was diagnosed based on CD1a positivity. At diagnosis, the score 
distributions were highly asymmetrical: the score was between 1 and 2 in 75.9% of cases, 
3-6 in 15.8%, and greater than 6 in 8.3%. Initial scores above 6 were highly predictive 
of reactivation and late complications.
Conclusion
This new LCH disease activity score provides an objective tool for assessing disease 
severity, both at diagnosis and during follow-up.
Key Words Histiocytosis, Langerhans cells, Disease activity, Clinical score
*This study was supported by a grant of the 
Korea Healthcare technology R&D Project, 
Ministry for Health, Welfare and Family 
Affairs, Republic of Korea (A080588-18).
Correspondence to
Jong-Jin Seo, M.D., Ph.D.
Division of Pediatric Hematology/ 
Oncolog, Department of Pediatrics, 
University of Ulsan College of Medicine & 
Asan Medical Center, 388-1, Pungnap- 




Ⓒ2011 Korean Society of Hematology
INTRODUCTION
Langerhans cell histiocytosis (LCH) is a rare disorder with 
diverse clinical presentations and prognosis [1, 2]. Patients 
with localized disease need minimum or even no treatment, 
whereas patients with multi-organ involvement, more fre-
quently young children, might benefit from cytotoxic drugs 
and steroids [1-3].
Disease activity is currently assessed using the Scoring 
System of the Histiocyte Society Protocol LCH III [4]. This 
assessment system is semi-quantitative, with the following 
4 categories: non-active disease, active disease-better, active 
disease-stable, and active disease-worse. The main drawback 
is that, by definition, each assessment is based on a compar-
ison of the situation before and after therapy (or a 6-week 
interval) and is, in part, subjective. Donadieu et al. [5] devel-
oped a new quantitative scoring system for LCH disease 
activity at diagnosis as an objective tool for therapeutic deci-
sion-making. This scoring system also had some limitations; 
the authors did not evaluate the involvements of risk organs 
in the endocrine system or the central nervous system (CNS) Korean J Hematol 2011;46:186-91.
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CNS-risk lesion involvement 1
Lymphadenopathy 1
Bone involvement
   Single 1
   Multifocal 2
Hematopoietic involvement (with or without bone marrow involvement
a))
   Anemia: hemoglobin ＜10 g/dL, infants ＜9 g/dL (exclusion of iron deficiency) 1
   Leukocytopenia: leukocytes ＜4.0×10
9/L 1
   Thrombocytopenia: platelets ＜100×10
9/L 1
Spleen involvement
   Enlargement ≥2 cm below costal margin 3
Liver involvement
   Enlargement ＞3 cm below costal margin and/or liver dysfunction 3
     (hyperbilirubinemiam, hypoalbuminemia, transaminases, ascites, edema) and/or histopathologic diagnosis
Lung involvement
   Typical changes on high-resolution computed tomography and/or histopathologic diagnosis 3
a)CD1a positivity.
and leukocytopenia. Furthermore, pulmonary function tests 
are not easy to perform in individuals less than 5 years 
of age, but this test was included in their study as an important 
tool.
To treat LCH appropriately, it is essential to investigate 
disease activity and choose the optimal treatment options. 
In this study, our aim was to develop a new quantitative 
scoring system for LCH disease activity at diagnosis that 
is easy to apply to patients and can help therapeutic deci-




Children diagnosed with LCH between March 1998 and 
February 2009 at Asan Medical Center and Hanyang 
University Hospital were included in this study. The diag-
nosis of LCH was confirmed by immunohistochemical stain-
ing with antibodies to CD1a, S100, or identification of 
Birbeck granules. Patient medical records were reviewed 
retrospectively for organ involvement at diagnosis, disease 
course, reactivation, and late sequelae. Single-system in-
volvement was defined as unifocal or multifocal involvement 
of a single organ system, whereas multisystem involvement 
was defined as the involvement of multiple organ systems, 
with or without organ dysfunction [1-3]. Risk organs were 
the liver, spleen, lung, and the hematopoietic system [1-3]. 
Reactivation was defined as the development of a new bone 
lesion (old or new site) or new organ involvement, while 
the patient was not receiving therapy [6]. According to the 
LCH III definition, response after a 6-week follow-up period 
was defined as better, intermediate, or worse. Better response 
was divided into 2 groups: complete resolution (non-active 
disease) and regression (active disease-better). Intermediate 
response was divided into two groups: mixed (new lesions 
in one site, regression in another site) and stable (unchanged). 
Worse response was defined as progression of signs or symp-
toms and/or the appearance of new lesions.
2. Definitions of the new clinical score
The new clinical score was developed by the authors based 
on basic biological data, radiographical findings, and clinical 
manifestations, as follows. Basic biological data: 1) hemoglo-
bin ＜10 g/dL, infants ＜9 g/dL (exclusion of iron deficiency), 
2) white blood cell count with differential ＜4.0×10
9/L, 3) 
platelet count 100×10
9/L, 4) bone marrow involvement 
(CD1a positivity), 5) elevated liver function tests and bilir-
ubin, 6) total proteins/albumin, 7) coagulation studies 
(prothrombin time [PT]/partial thromboplastin time [PTT], 
fibrinogen), and 8) abnormal urine osmolarity after overnight 
water deprivation. Radiological findings: 1) chest radiograph: 
interstitial pulmonary involvement, bullae, pneumothorax, 
or typical changes on high-resolution CT, and/or histopatho-
logic diagnosis, and 2) skeletal radiologic survey: osteolytic 
lesion. Clinical manifestations: 1) fever, defined as temper-
ature elevated above 38.5
oC, 2) pulmonary function: tachyp-
nea (60/m in infants, 30/m in children), cough, chest pain, 
dyspnea, cyanosis, 3) hepatomegaly ＞3 cm below costal 
margin, 4) splenomegaly ＞2 cm below costal margin, 5) 
bone (multifocal), 6) risk of CNS involvement: lesions in 
the orbital, temporal/mastoid, sphenoidal, zygomatical, or 
ethmoidal bones, maxilla, sinuses or anterior or middle cra-
nial fossa, with intracranial soft tissue extension, demon-
strated on magnetic resonance imaging (MRI); vault lesions Korean J Hematol 2011;46:186-91.
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Fig. 1. The clinical score distribution at initial diagnosis. Scores between
1 and 2 were assigned to 75.9% (N=101) of cases, between 3 and 6 to 
15.8% (N=21), and more than 6 to 8.3% (N=11). The number of 
patients with a score of 1 or 2 was significantly higher than the other 
groups.
Fig. 2. The age distribution of 3 clinical score categories. In the group 
with scores of 1 or 2, the number of patients who were less than 2 years
of age was higher than in the group with scores higher than 3. However,
this difference did not reach statistical significance.








Wait and see, n (%) 6 (5.9%) 0 (0%) 0 (0%)
Local therapy, n (%) 39 (49.5%) 0 (0%) 0 (0%)
Systemic therapy, n (%) 56 (55.4%) 21 (100%) 11 (100%)
were not regarded as “CNS risk” lesions, and 7) lymphade-
nopathy. Scoring was done according to the contribution 
of each factor to the clinical course. Risk organ involvement 
was regarded as high risk and most important. The final 
scoring system is described in Table 1.
3. Statistical analysis
The SPSS 13.0 (SPSS, Chicago, IL) statistical software pack-
age was used for all statistical analyses. Scores of different 
groups at diagnosis were compared using the Kruskal-Wallis 
test. The reactivation-free survival rate was estimated using 
the Kaplan-Meier method. Differences in survival rates ac-
cording to the scores were compared using the log-rank 
test. A P-value＜0.05 was regarded statistically significant.
RESULTS
1. Patients characteristics
One hundred fifty-one patients (69 female, 82 males) were 
available, but only 133 patients (59 female, 74 male) were 
included in this study. The data from 18 patients were not 
suitable for evaluation, because their complete data was not 
available. The median age of the 133 patients was 52 months 
(range, 0.1-178 months) and median follow-up duration was 
125 months (range, 6-236 months).
2. Comparisons of the clinical courses according to the clin-
ical scores
The score distribution at initial diagnosis was highly asym-
metrical and is shown in Fig. 1. The score was between 
1 and 2 in 75.9% (N=101) of cases, 3-6 in 15.8% (N=21) 
and more than 6 in 8.3% (N=11). The number of patients 
with a score of 1 or 2 was significantly higher than the 
other groups. In the groups with a score of 1 or 2, the 
number of patients who were less than 2 years of age was 
higher than in the groups whose scores were more than 
3, but this did not reach statistical significance (Fig. 2). Six 
patients (4.5%) were not treated and follow-up studies re-
vealed resolutions of the lesions; 39 patients (29.3%) had 
single bone involvement at diagnosis and received local ther-
apy, such as curettage. All the patients who were not treated 
or received only local therapy were patients in the groups 
with a score of 1 or 2. Patients who had a score of more 
than 3 were all treated with systemic chemotherapy, whereas 
only 55.5% (56/101) of patients in score 1 or 2 groups received 
systemic chemotherapy (Table 2). When we compared the 
treatment response at 6 weeks, 93.1% (94/101) of the patients 
with scores of 1 or 2 had relevant to better responses 
(complete resolution, 43.6%; regression, 49.5%), whereas on-
ly 4 cases (4.0%) in this group had a worse response. In 
the group with scores of 3 to 5, 76.2% (16/21) of the patients 
fit the criteria for better response (complete resolution, 
38.1%; regression, 38.1%), and the rest of the patients (5/21) 
proved to be stable. In the group with scores above 6, 27.3% 
of the patients (3/11) had a better response (regression, 
27.3%) and none of the patients had complete resolution, 
whereas 36.3% of the patients (4/11) were observed to have 
a worse response (Table 3). The reactivation-free survival 
curves (Fig. 3) differed among these 3 score categories, with 
significantly higher number of reactivations occurring in Korean J Hematol 2011;46:186-91.
New clinical score in LCH 189
Fig. 3. The curve of reactivation free survival rate. The reactivation-free
survival curves during follow-up in the high score group (＞6) was 
significantly lower than in groups with lower scores.









   Complete resolution 44 (43.6%) 8 (38.1%) 0 (0%)
   Regression 50 (49.5%) 8 (38.1%) 3 (27.3%)
Intermediate
   Mixed 1 (0.9%) 0 (0%) 2 (18.2%)
   Stable 2 (2.0%) 5 (23.8%) 2 (18.2%)
Worse 4 (4.0%) 0 (0%) 4 (36.3%)







DI 3 (3.0%) 1 (4.8%) 0 (0%)
Endocrinopathy 0 (0%) 1 (4.8%) 2 (18.2%)
Neurologic disorder 0 (0%) 0 (0%) 3 (27.3%)
Pulmonary sequelae 0 (0%) 1 (4.8%) 1 (9.1%)
Orthopedic sequelae 5 (5.0%) 0 (0%) 0 (0%)
Hearing impairment 0 (0%) 1 (4.8%) 1 (9.1%)
the high score group (＞6) than in the groups with lower 
scores during follow-up. In terms of late sequelae, orthopedic 
sequelae occurred more frequently in lower score groups 
(scores 1 and 2) and was associated with bone involvement 
(Table 4).
DISCUSSION
LCH has a variable clinical spectrum, and the course of 
the disease is unpredictable, varying from spontaneous re-
gression and resolution to rapid progression and death or 
recurrence [1-3]. Patients with localized disease generally 
have a good prognosis and need minimal or even no 
treatment. Bone involvement with or without other asso-
ciated sites is the most common manifestation of LCH and 
has been observed in 80-100% of cases [7]. The bones most 
frequently involved in LCH patients, in a study of 503 osseous 
lesions, were the skull (27%), femur (13%), mandible/maxilla 
(11%), pelvis (10%), vertebral bodies (8%), ribs (8%), hume-
rus (5%), and tibia (3%) [8]. The prognosis is dependent 
on the number of organs involved, as well as the presence 
of organ dysfunction, and to a lesser degree, the age of the 
patient at the onset of the disease [1-3]. Involvement of 
the spleen, lung, liver, or hematopoietic system also contrib-
utes to a poor prognosis [1]. In one large study of 101 children 
with LCH, the overall survival rate for all was 79% at 1 
year, 74% at 3 years, and 71% at 5 years; however, in patients 
with liver or spleen involvement, the 1-year survival was 
33% and 5-year survival was just 25% [9].
More detailed clinical information will help delineate the 
different entities of LCH clearly and may facilitate the devel-
opment of an advanced classification system as a basis for 
selecting the appropriate therapeutic approach. Therefore, 
factors influencing the outcome of LCH must be identified 
to prevent or facilitate the treatment of disease progression 
and relapse. A quantitative disease activity score can help 
therapeutic decision-making, especially in complex sit-
uations such as multi-organ involvement. We developed a 
new quantitative scoring system for LCH disease activity, 
which is easy to practice and can help therapeutic deci-
sion-making in this disease. It may also serve to standardize 
the management of patients with very severe forms of LCH, 
who need more effective treatments.
According to our new clinical score, most of the patients 
were assigned scores of 1 and 2 (75.9%). The patients with 
low scores (1-2) did not have life-threatening disease, and 
the reactivation rate was lower in this group than in the 
higher score groups (Fig. 3). Most of the patients in this 
group were diagnosed with single or multiple bone 
involvement. Of these patients, only 55.4% received systemic 
chemotherapy, and 4.0% of the patients had a worse response 
at the 6-week evaluation. On the basis of these data, the 
treatment plan of these patients has to be simplified, and 
more attention may be needed to prevent functional sequelae. 
All the patients with moderate scores (3-6) received chemo-
therapy, and none of them showed progression at the 6-week 
evaluation. This group of patients showed reactivation-free 
survival rates comparable to the lower score group (1-2) 
(86.5% vs. 77.9%). Patients with high scores (＞6) showed 
a poor short-term outlook: 36.3% of the patients progressed 
at 6 weeks and the reactivation-free survival rate was 45.5%. 
These results are much worse than for other groups. Such 
patients may therefore qualify for aggressive chemotherapy 
or even stem cell transplantation (Table 2, 3).
Comparing our scoring system with that of Donadieu et 
al. [5], their scoring system does not take bone involvement Korean J Hematol 2011;46:186-91.
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into account, even though this is the most frequent 
manifestation. In addition, only bone pain was taken into 
account, and this is a subjective symptom and responds very 
rapidly to various treatments, including non-steroidal anti- 
inflammatory drugs. Radiological outcome was poorly char-
acterized and was not used to assess disease activity or 
progression. Further, the score did not evaluate endocrine 
or neurological sequelae. Our new clinical scoring system 
accounts for all these factors and uses a simplified protocol.
The etiology and pathogenesis of LCH have remained an 
enigma [10-12]. The mechanisms of LCH cell development 
are still not completely understood. However, several mecha-
nisms might play important roles, including multiple chro-
mosomal alterations that have been found in LCH cells 
[13-15], and clonal proliferation of LCH cells [16-19]. Although 
definitive and consistent molecular events leading to clonal 
proliferation are unclear, high levels of cytokines are secreted 
by LCH cells, as well as by bystander cells in LCH lesions 
[20-22]. These cytokines could contribute to the proliferation 
and differentiation of LCH cell progenitors and could play 
a role in preventing LCH cells from maturing. The clinical 
course of LCH is quite variable, and we divided the LCH 
patients into 3 groups according to the new clinical scores. 
With this classification, we observed differences in clinical 
courses and outcomes among these 3 groups. Roughly, most 
of the patients with scores 1 and 2 have single system disease, 
especially bone involvement, and those with scores 3-5 have 
multisystem disease, without risk organ involvement, where-
as patients with scores ＞6 have multisystem disease, with 
risk organ involvement. We pinpoint correlations between 
the clinical variability and different pathogeneses, albeit with 
caution.
The major limitation of this scoring system is that it has 
been applied to only a small patient dataset, in a retrospective 
fashion. In particular, a precise evaluation of late sequelae 
was not possible. We stress tha t  it  n e e d s  t o  b e  v a l i d a t e d  
prospectively in larger patient populations. Future studies 
on the biology of LCH should enable us to better understand 
the pathology and mechanisms responsible for the develop-
ment of LCH and its variable clinical course.
Despite these limitations, our new clinical score has the 
merit of being able to quantify LCH disease activity at 
diagnosis. We expect that this new clinical score can help 
therapeutic decision-making and formulation of improved 
follow-up plans in this variable disease. It may also serve 
to standardize the treatment of patients with severe forms 
of LCH, who need more intensive treatments.
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